本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Cue Biopharma, Inc.

0.9692
+0.00420.44%
盤後0.96920.00000.00%16:05 EDT
成交量:5.96萬
成交額:5.81萬
市值:6,139.91萬
市盈率:-1.08
高:0.9992
開:0.9800
低:0.9600
收:0.9650
資料載入中...

公司資料

公司名字:
Cue Biopharma, Inc.
交易所:
NASDAQ
成立時間:
2014
員工人數:
53
公司地址:
40 Guest Street,Boston,Massachusetts,United States
郵編:
02135
電話:
傳真:
- -
簡介:
Cue Biopharma, Inc.於2014年12月31日在特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司,設計了一類新型的注射療法,以選擇性地在患者體內直接參与和調節靶向的、與疾病相關的T細胞。該公司的願景是通過生成一類新的T細胞接合劑,用於選擇性調節疾病特異性T細胞,將大自然的信號或“線索”轉化為蛋白質療法。

董事

名稱
職位
Daniel R. Passeri
Chief Executive Officer, President and Director
Peter A. Kiener
Chairman and Director
Anthony DiGiandomencio
Director
Barry Simon
Director
Cameron Gray
Director
Christopher Marlett
Director
Steven McKnight
Director

股東

名稱
職位
Daniel R. Passeri
Chief Executive Officer, President and Director
Anish Suri
Senior Vice President and Chief Scientific Officer
Colin G. Sandercock
Senior Vice President, General Counsel and Secretary
Ken Pienta
Chief Medical Officer
Kerri Ann Millar
Vice President, Finance
Rodolfo Chaparro
Executive Vice President, Head of Immunology
Ronald Seidel, III
Executive Vice President, Head of Research and Development